Cancer

Senti Bio to Present at the Citizens JMP Life Sciences Conference

Live video webcast presentation on Thursday, May 8th at 1:00 PM ET Presentation will highlight the recently announced positive preliminary…

8 months ago

Long Beach Medical Center Makes History with World’s First Robotic Hip Revision Using Mako Total Hip with 5.0 Software

LONG BEACH, Calif., April 29, 2025 /PRNewswire/ -- MemorialCare Long Beach Medical Center has made history by becoming the first hospital globally…

8 months ago

Long Beach Medical Center Makes History with World’s First Robotic Hip Revision Using Mako Total Hip with 5.0 Software

LONG BEACH, Calif., April 29, 2025 /PRNewswire/ -- MemorialCare Long Beach Medical Center has made history by becoming the first hospital globally…

8 months ago

Long Beach Medical Center Makes History with World’s First Robotic Hip Revision Using Mako Total Hip with 5.0 Software

LONG BEACH, Calif., April 29, 2025 /PRNewswire/ -- MemorialCare Long Beach Medical Center has made history by becoming the first hospital globally…

8 months ago

NeoGenomics and Ultima Genomics collaborate to expand clinical test offerings in Oncology using the UG 100 sequencing platform

FORT MYERS, Fla. and FREMONT, Calif., April 29, 2025 /PRNewswire/ -- NeoGenomics, Inc. (Nasdaq:NEO), a leading provider of oncology diagnostic…

8 months ago

Lirum Therapeutics’ LX-101 New Positive Data Selected for Presentation at the 2025 American Association for Cancer Research (AACR) Annual Meeting

New York, NY, April 29, 2025 (GLOBE NEWSWIRE) -- Lirum Therapeutics, Inc. (“Lirum”), an innovative clinical-stage biopharmaceutical company focused on…

8 months ago

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net…

8 months ago

Sandoz enters global collaboration license agreement with Henlius to commercialize leading oncology therapy, ipilimumab, in multiple indications

MEDIA RELEASE Agreement offers rights to commercialize proposed biosimilar of Yervoy®* for treatment of variety of cancer types, targeting net…

8 months ago

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly…

8 months ago

Affimed Shows Higher Exposure of AFM24 is Associated with Significantly Higher Response Rates and Progression-Free Survival in Refractory NSCLC Patients at AACR Annual Meeting

An exposure-outcome analysis in 72 patients with refractory non-small cell lung cancer (NSCLC) who received AFM24 at 480 mg weekly…

8 months ago